APO Research
Talk to an analyst

APO RESEARCH · REPORT

Transthyretin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Transthyretin Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchTransthyretin Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Transthyretin Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Transthyretin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Transthyretin Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Transthyretin Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Transthyretin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Transthyretin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Transthyretin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Transthyretin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Transthyretin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Transthyretin market include Alnylam Pharmaceuticals Inc, Arcturus Therapeutics Inc, Ionis Pharmaceuticals Inc, Neurimmune Holding AG, Prothena Corp Plc, Regeneron Pharmaceuticals Inc and Pfizer Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Transthyretin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Transthyretin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Transthyretin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Transthyretin market size, projected growth trends, production technologies, key applications, and end-use industries.

Transthyretin Segment by Company

Alnylam Pharmaceuticals Inc

Arcturus Therapeutics Inc

Ionis Pharmaceuticals Inc

Neurimmune Holding AG

Prothena Corp Plc

Regeneron Pharmaceuticals Inc

Pfizer Inc

Transthyretin Segment by Type

AG-10

Inotersen Sodium

EDE-1307

CRX-1008

ALN-TTRsc02

Others

Transthyretin Segment by Application

Alzheimer's Disease

Familial Amyloid Neuropathies

Cardomyopathy

Neuropathy

Others

Transthyretin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Transthyretin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Transthyretin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Transthyretin significant trends, drivers, influence factors in global and regions.

6. To analyze Transthyretin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transthyretin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Transthyretin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transthyretin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Transthyretin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Transthyretin industry.

Chapter 3: Detailed analysis of Transthyretin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Transthyretin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Transthyretin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Transthyretin Industry Trends Table 2. Transthyretin Industry Drivers Table 3. Transthyretin Industry Opportunities and Challenges Table 4. Transthyretin Industry Restraints Table 5. Global Transthyretin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Transthyretin Revenue Share by Company (2021-2026) Table 7. Global Transthyretin Sales Volume by Company (k units) & (2021-2026) Table 8. Global Transthyretin Sales Volume Share by Company (2021-2026) Table 9. Global Transthyretin Average Price (US$/unit) of Company (2021-2026) Table 10. Global Transthyretin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Transthyretin Key Company Manufacturing Base & Headquarters Table 12. Global Transthyretin Company, Product Type & Application Table 13. Global Transthyretin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Transthyretin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of AG-10 Table 18. Significant Companies of Inotersen Sodium Table 19. Significant Companies of EDE-1307 Table 20. Significant Companies of CRX-1008 Table 21. Significant Companies of ALN-TTRsc02 Table 22. Significant Companies of Others Table 23. Global Transthyretin Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Transthyretin Sales Volume by Type (2021-2026) & (k units) Table 25. Global Transthyretin Sales Volume by Type (2027-2032) & (k units) Table 26. Global Transthyretin Sales Volume Share by Type (2021-2026) Table 27. Global Transthyretin Sales Volume Share by Type (2027-2032) Table 28. Global Transthyretin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Transthyretin Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Transthyretin Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Transthyretin Sales Value Share by Type (2021-2026) Table 32. Global Transthyretin Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Alzheimer's Disease Table 34. Significant Companies of Familial Amyloid Neuropathies Table 35. Significant Companies of Cardomyopathy Table 36. Significant Companies of Neuropathy Table 37. Significant Companies of Others Table 38. Global Transthyretin Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Transthyretin Sales Volume by Application (2021-2026) & (k units) Table 40. Global Transthyretin Sales Volume by Application (2027-2032) & (k units) Table 41. Global Transthyretin Sales Volume Share by Application (2021-2026) Table 42. Global Transthyretin Sales Volume Share by Application (2027-2032) Table 43. Global Transthyretin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Transthyretin Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Transthyretin Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Transthyretin Sales Value Share by Application (2021-2026) Table 47. Global Transthyretin Sales Value Share by Application (2027-2032) Table 48. Global Transthyretin Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 49. Global Transthyretin Sales by Region (2021-2026) & (k units) Table 50. Global Transthyretin Sales Market Share by Region (2021-2026) Table 51. Global Transthyretin Sales by Region (2027-2032) & (k units) Table 52. Global Transthyretin Sales Market Share by Region (2027-2032) Table 53. Global Transthyretin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Transthyretin Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Transthyretin Sales Value Share by Region (2021-2026) Table 56. Global Transthyretin Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Transthyretin Sales Value Share by Region (2027-2032) Table 58. Global Transthyretin Market Average Price (US$/unit) by Region (2021-2026) Table 59. Global Transthyretin Market Average Price (US$/unit) by Region (2027-2032) Table 60. Global Transthyretin Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 61. Global Transthyretin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Transthyretin Sales by Country (2021-2026) & (k units) Table 63. Global Transthyretin Sales Market Share by Country (2021-2026) Table 64. Global Transthyretin Sales by Country (2027-2032) & (k units) Table 65. Global Transthyretin Sales Market Share by Country (2027-2032) Table 66. Global Transthyretin Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Transthyretin Sales Value Market Share by Country (2021-2026) Table 68. Global Transthyretin Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Transthyretin Sales Value Market Share by Country (2027-2032) Table 70. Alnylam Pharmaceuticals Inc Company Information Table 71. Alnylam Pharmaceuticals Inc Business Overview Table 72. Alnylam Pharmaceuticals Inc Transthyretin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Alnylam Pharmaceuticals Inc Transthyretin Product Portfolio Table 74. Alnylam Pharmaceuticals Inc Recent Development Table 75. Arcturus Therapeutics Inc Company Information Table 76. Arcturus Therapeutics Inc Business Overview Table 77. Arcturus Therapeutics Inc Transthyretin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Arcturus Therapeutics Inc Transthyretin Product Portfolio Table 79. Arcturus Therapeutics Inc Recent Development Table 80. Ionis Pharmaceuticals Inc Company Information Table 81. Ionis Pharmaceuticals Inc Business Overview Table 82. Ionis Pharmaceuticals Inc Transthyretin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Ionis Pharmaceuticals Inc Transthyretin Product Portfolio Table 84. Ionis Pharmaceuticals Inc Recent Development Table 85. Neurimmune Holding AG Company Information Table 86. Neurimmune Holding AG Business Overview Table 87. Neurimmune Holding AG Transthyretin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Neurimmune Holding AG Transthyretin Product Portfolio Table 89. Neurimmune Holding AG Recent Development Table 90. Prothena Corp Plc Company Information Table 91. Prothena Corp Plc Business Overview Table 92. Prothena Corp Plc Transthyretin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Prothena Corp Plc Transthyretin Product Portfolio Table 94. Prothena Corp Plc Recent Development Table 95. Regeneron Pharmaceuticals Inc Company Information Table 96. Regeneron Pharmaceuticals Inc Business Overview Table 97. Regeneron Pharmaceuticals Inc Transthyretin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Regeneron Pharmaceuticals Inc Transthyretin Product Portfolio Table 99. Regeneron Pharmaceuticals Inc Recent Development Table 100. Pfizer Inc Company Information Table 101. Pfizer Inc Business Overview Table 102. Pfizer Inc Transthyretin Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Pfizer Inc Transthyretin Product Portfolio Table 104. Pfizer Inc Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. Transthyretin Distributors List Table 108. Transthyretin Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Transthyretin Product Image Figure 2. Global Transthyretin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Transthyretin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Transthyretin Sales (2021-2032) & (k units) Figure 5. Global Transthyretin Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Transthyretin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. AG-10 Image Figure 10. Inotersen Sodium Image Figure 11. EDE-1307 Image Figure 12. CRX-1008 Image Figure 13. ALN-TTRsc02 Image Figure 14. Others Image Figure 15. Global Transthyretin Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Transthyretin Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Transthyretin Sales Volume Share by Type (2021-2032) Figure 18. Global Transthyretin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Transthyretin Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Transthyretin Sales Value Share by Type (2021-2032) Figure 21. Alzheimer's Disease Image Figure 22. Familial Amyloid Neuropathies Image Figure 23. Cardomyopathy Image Figure 24. Neuropathy Image Figure 25. Others Image Figure 26. Global Transthyretin Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Transthyretin Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Transthyretin Sales Volume Share by Application (2021-2032) Figure 29. Global Transthyretin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Transthyretin Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Transthyretin Sales Value Share by Application (2021-2032) Figure 32. Global Transthyretin Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 33. Global Transthyretin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Transthyretin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Transthyretin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Transthyretin Sales Value (2021-2032) & (US$ Million) Figure 37. North America Transthyretin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Transthyretin Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Transthyretin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Transthyretin Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Transthyretin Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Transthyretin Sales Value (2021-2032) & (US$ Million) Figure 43. South America Transthyretin Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Transthyretin Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Transthyretin Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Transthyretin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Transthyretin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Transthyretin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Transthyretin Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Transthyretin Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • AG-10
  • Inotersen Sodium
  • EDE-1307
  • CRX-1008
  • ALN-TTRsc02
  • Others
Applications
  • Alzheimer's Disease
  • Familial Amyloid Neuropathies
  • Cardomyopathy
  • Neuropathy
  • Others
Companies covered
  • Alnylam Pharmaceuticals Inc
  • Arcturus Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Neurimmune Holding AG
  • Prothena Corp Plc
  • Regeneron Pharmaceuticals Inc
  • Pfizer Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Transthyretin Sales Value (2021-2032)
  4. 1.2.2 Global Transthyretin Sales Volume (2021-2032)
  5. 1.2.3 Global Transthyretin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Transthyretin Market Dynamics
  1. 2.1 Transthyretin Industry Trends
  2. 2.2 Transthyretin Industry Drivers
  3. 2.3 Transthyretin Industry Opportunities and Challenges
  4. 2.4 Transthyretin Industry Restraints
3 Transthyretin Market by Company
  1. 3.1 Global Transthyretin Company Revenue Ranking in 2025
  2. 3.2 Global Transthyretin Revenue by Company (2021-2026)
  3. 3.3 Global Transthyretin Sales Volume by Company (2021-2026)
  4. 3.4 Global Transthyretin Average Price by Company (2021-2026)
  5. 3.5 Global Transthyretin Company Ranking (2024-2026)
  6. 3.6 Global Transthyretin Company Manufacturing Base and Headquarters
  7. 3.7 Global Transthyretin Company Product Type and Application
  8. 3.8 Global Transthyretin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Transthyretin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Transthyretin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Transthyretin Market by Type
  1. 4.1 Transthyretin Type Introduction
  2. 4.1.1 AG-10
  3. 4.1.2 Inotersen Sodium
  4. 4.1.3 EDE-1307
  5. 4.1.4 CRX-1008
  6. 4.1.5 ALN-TTRsc02
  7. 4.1.6 Others
  8. 4.2 Global Transthyretin Sales Volume by Type
  9. 4.2.1 Global Transthyretin Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Transthyretin Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Transthyretin Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Transthyretin Sales Value by Type
  13. 4.3.1 Global Transthyretin Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Transthyretin Sales Value by Type (2021-2032)
  15. 4.3.3 Global Transthyretin Sales Value Share by Type (2021-2032)
5 Transthyretin Market by Application
  1. 5.1 Transthyretin Application Introduction
  2. 5.1.1 Alzheimer's Disease
  3. 5.1.2 Familial Amyloid Neuropathies
  4. 5.1.3 Cardomyopathy
  5. 5.1.4 Neuropathy
  6. 5.1.5 Others
  7. 5.2 Global Transthyretin Sales Volume by Application
  8. 5.2.1 Global Transthyretin Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Transthyretin Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Transthyretin Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Transthyretin Sales Value by Application
  12. 5.3.1 Global Transthyretin Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Transthyretin Sales Value by Application (2021-2032)
  14. 5.3.3 Global Transthyretin Sales Value Share by Application (2021-2032)
6 Transthyretin Regional Sales and Value Analysis
  1. 6.1 Global Transthyretin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Transthyretin Sales by Region (2021-2032)
  3. 6.2.1 Global Transthyretin Sales by Region: 2021-2026
  4. 6.2.2 Global Transthyretin Sales by Region (2027-2032)
  5. 6.3 Global Transthyretin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Transthyretin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Transthyretin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Transthyretin Sales Value by Region (2027-2032)
  9. 6.5 Global Transthyretin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Transthyretin Sales Value (2021-2032)
  12. 6.6.2 North America Transthyretin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Transthyretin Sales Value (2021-2032)
  15. 6.7.2 Europe Transthyretin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Transthyretin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Transthyretin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Transthyretin Sales Value (2021-2032)
  21. 6.9.2 South America Transthyretin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Transthyretin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Transthyretin Sales Value Share by Country, 2025 VS 2032
7 Transthyretin Country-level Sales and Value Analysis
  1. 7.1 Global Transthyretin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Transthyretin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Transthyretin Sales by Country (2021-2032)
  4. 7.3.1 Global Transthyretin Sales by Country (2021-2026)
  5. 7.3.2 Global Transthyretin Sales by Country (2027-2032)
  6. 7.4 Global Transthyretin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Transthyretin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Transthyretin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Transthyretin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Transthyretin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Transthyretin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Transthyretin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Transthyretin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Transthyretin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Transthyretin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Transthyretin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Transthyretin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Transthyretin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Transthyretin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Transthyretin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Transthyretin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Transthyretin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Transthyretin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Transthyretin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Transthyretin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Transthyretin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Transthyretin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Transthyretin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Transthyretin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Transthyretin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Transthyretin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Transthyretin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Transthyretin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Transthyretin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Transthyretin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Transthyretin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Transthyretin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Transthyretin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Transthyretin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Transthyretin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Transthyretin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Transthyretin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Transthyretin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Transthyretin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Transthyretin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Transthyretin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Transthyretin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Transthyretin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Transthyretin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Transthyretin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Transthyretin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Transthyretin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Transthyretin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Transthyretin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Transthyretin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Transthyretin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Transthyretin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Transthyretin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Transthyretin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Transthyretin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Transthyretin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Transthyretin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Transthyretin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Transthyretin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Transthyretin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Transthyretin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Transthyretin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Transthyretin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Transthyretin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Transthyretin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Transthyretin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Transthyretin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Transthyretin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Transthyretin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Transthyretin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Transthyretin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Transthyretin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Transthyretin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Transthyretin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Transthyretin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Transthyretin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Transthyretin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Transthyretin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Transthyretin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Transthyretin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Transthyretin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Transthyretin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Transthyretin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Transthyretin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Transthyretin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Transthyretin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Transthyretin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alnylam Pharmaceuticals Inc
  2. 8.1.1 Alnylam Pharmaceuticals Inc Company Information
  3. 8.1.2 Alnylam Pharmaceuticals Inc Business Overview
  4. 8.1.3 Alnylam Pharmaceuticals Inc Transthyretin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Alnylam Pharmaceuticals Inc Transthyretin Product Portfolio
  6. 8.1.5 Alnylam Pharmaceuticals Inc Recent Developments
  7. 8.2 Arcturus Therapeutics Inc
  8. 8.2.1 Arcturus Therapeutics Inc Company Information
  9. 8.2.2 Arcturus Therapeutics Inc Business Overview
  10. 8.2.3 Arcturus Therapeutics Inc Transthyretin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Arcturus Therapeutics Inc Transthyretin Product Portfolio
  12. 8.2.5 Arcturus Therapeutics Inc Recent Developments
  13. 8.3 Ionis Pharmaceuticals Inc
  14. 8.3.1 Ionis Pharmaceuticals Inc Company Information
  15. 8.3.2 Ionis Pharmaceuticals Inc Business Overview
  16. 8.3.3 Ionis Pharmaceuticals Inc Transthyretin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ionis Pharmaceuticals Inc Transthyretin Product Portfolio
  18. 8.3.5 Ionis Pharmaceuticals Inc Recent Developments
  19. 8.4 Neurimmune Holding AG
  20. 8.4.1 Neurimmune Holding AG Company Information
  21. 8.4.2 Neurimmune Holding AG Business Overview
  22. 8.4.3 Neurimmune Holding AG Transthyretin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Neurimmune Holding AG Transthyretin Product Portfolio
  24. 8.4.5 Neurimmune Holding AG Recent Developments
  25. 8.5 Prothena Corp Plc
  26. 8.5.1 Prothena Corp Plc Company Information
  27. 8.5.2 Prothena Corp Plc Business Overview
  28. 8.5.3 Prothena Corp Plc Transthyretin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Prothena Corp Plc Transthyretin Product Portfolio
  30. 8.5.5 Prothena Corp Plc Recent Developments
  31. 8.6 Regeneron Pharmaceuticals Inc
  32. 8.6.1 Regeneron Pharmaceuticals Inc Company Information
  33. 8.6.2 Regeneron Pharmaceuticals Inc Business Overview
  34. 8.6.3 Regeneron Pharmaceuticals Inc Transthyretin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Regeneron Pharmaceuticals Inc Transthyretin Product Portfolio
  36. 8.6.5 Regeneron Pharmaceuticals Inc Recent Developments
  37. 8.7 Pfizer Inc
  38. 8.7.1 Pfizer Inc Company Information
  39. 8.7.2 Pfizer Inc Business Overview
  40. 8.7.3 Pfizer Inc Transthyretin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Inc Transthyretin Product Portfolio
  42. 8.7.5 Pfizer Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Transthyretin Value Chain Analysis
  2. 9.1.1 Transthyretin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Transthyretin Sales Mode & Process
  6. 9.2 Transthyretin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Transthyretin Distributors
  9. 9.2.3 Transthyretin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst